HC Wainwright Has Negative Estimate for argenex Q2 Earnings

Key Points

• HC Wainwright lowered its Q2 2027 EPS estimate for argenx to $7.83 from $8.41, while maintaining a “Buy” rating and a $1,202 price target.
• argenx’s latest results exceeded expectations, with EPS of $7.80 versus the $7.44 consensus and quarterly revenue of $1.75 billion.
• Analyst sentiment remains broadly positive: the stock has a “Moderate Buy” consensus rating and an average price target of $1,142.37, although several firms have recently adjusted their targets.

argenex SE (NASDAQ:ARGX - Free Report) - Analysts at HC Wainwright cut their Q2 2027 earnings per share estimates for shares of argenex in a note issued to investors on Friday, October 23rd. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $7.83 for the quarter, down from their prior estimate of $8.41. HC Wainwright currently has a "Buy" rating and a $1,202.00 price objective on the stock. The consensus estimate for argenex's current full-year earnings is $25.79 per share. HC Wainwright also issued estimates for argenex's Q3 2027 earnings at $9.39 EPS and Q4 2027 earnings at $9.76 EPS.

argenex (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Friday, October 23rd. The company reported $7.80 EPS for the quarter, topping analysts' consensus estimates of $7.44 by $0.36. argenex had a return on equity of 47.70% and a net margin of 31.66%. The firm had revenue of $1.75 billion for the quarter.

Several other equities research analysts have also commented on ARGX. Wells Fargo & Company lowered their price objective on argenex from $1,356.00 to $1,336.00 and set an "overweight" rating on the stock in a research report on Friday. Jefferies Financial Group restated a "buy" rating on shares of argenex in a research report on Monday, September 14th. Weiss Ratings restated a "hold (c)" rating on shares of argenex in a research note on Wednesday. UBS Group raised argenex from a "neutral" rating to a "buy" rating and upped their target price for the stock from $960.00 to $1,400.00 in a research note on Wednesday, August 26th. Finally, Barclays reiterated a "buy" rating on shares of argenex in a research report on Monday, September 7th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,142.37.

argenex Stock Performance

Shares of ARGX stock opened at $873.71 on Monday. The stock has a 50 day moving average of $956.62 and a 200 day moving average of $886.34. The stock has a market cap of $54.95 billion, a P/E ratio of 30.49, a P/E/G ratio of 0.89 and a beta of 0.44. argenex has a twelve month low of $661.85 and a twelve month high of $1,072.75.

Institutional Investors Weigh In On argenex

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sigma Planning Corp purchased a new stake in shares of argenex during the third quarter worth $1,027,000. Signaturefd LLC raised its position in shares of argenex by 2.6% in the third quarter. Signaturefd LLC now owns 2,129 shares of the company's stock valued at $2,041,000 after buying an additional 54 shares during the last quarter. BG Investment Services LLC acquired a new stake in shares of argenex in the third quarter valued at about $1,397,000. Sowell Financial Services LLC raised its position in shares of argenex by 25.8% in the third quarter. Sowell Financial Services LLC now owns 459 shares of the company's stock valued at $440,000 after buying an additional 94 shares during the last quarter. Finally, Guardian Partners Inc. purchased a new position in shares of argenex in the third quarter worth about $863,000. Institutional investors and hedge funds own 60.32% of the company's stock.

Key argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Strong quarterly results: argenx reported $7.80 in EPS, exceeding the $7.44 consensus estimate, while revenue reached $1.75 billion. Product net sales grew 54% year over year to $1.7 billion, and operating profit was $486 million. argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Bullish analyst support: Morgan Stanley raised its price target from $1,140 to $1,190 and maintained an “overweight” rating. Wells Fargo also maintained “overweight” despite trimming its target from $1,356 to $1,336. Jefferies called the post-news setup a potentially attractive entry point. Morgan Stanley rating
• Neutral Sentiment: Targets remain above the market price, but revisions are mixed: Guggenheim lowered its target from $1,185 to $1,120 while keeping a “buy” rating. Robert W. Baird raised its target from $823 to $861 but retained a “neutral” rating, and RBC reportedly cut its target. These changes suggest continued confidence in long-term value but more cautious near-term expectations. Guggenheim rating
• Negative Sentiment: Clinical-development setback is overshadowing the earnings beat: Reports highlighted a surprise testing setback for argenx’s core drug, raising concerns about future growth, product expansion and execution. That issue appears to be driving the weaker investor reaction despite the company’s strong sales and profitability. argenx testing setback

argenex Company Profile

argenx SE NASDAQ: ARGX is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx's lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.